Minaris Advanced Therapies: A New Era in Cell Therapy
Minaris Advanced Therapies has officially launched as a leading global partner focused on the development, manufacturing, and testing of cell therapies. This innovative company was introduced at the annual ISCT conference. The formation of Minaris represents a strategic alliance between Minaris Regenerative Medicine and the U.S. and U.K. divisions of WuXi Advanced Therapies.
Bringing Together Expertise and Innovation
Headquartered in Philadelphia, Minaris Advanced Therapies leverages cutting-edge facilities located in strategic regions across the globe, including the United States, Europe, and Asia-Pacific. These modern facilities are equipped for commercial production and are already operational, producing clinical and commercial products efficiently.
Comprehensive Manufacturing Capabilities
Minaris Advanced Therapies boasts an impressive portfolio, having delivered over 7,500 GMP batches to date. This strong track record highlights the company’s ability to support clinical-stage and commercial products. They currently manufacture two commercial cell therapies and provide testing services for more than 27 additional products. Their extensive capabilities extend to innovative platforms, development, and manufacturing expertise in cell therapies and viral vectors.
Addressing Industry Challenges
Iain Baird, the chairman of Minaris Advanced Therapies, commented on the challenges that CDMOs have faced in the cell therapy sector. He emphasizes the company's mission to overcome these obstacles and facilitate the successful commercialization of groundbreaking therapies. The dedication to accelerating development and manufacturing processes is a key focus.
A Robust Team and Efficient Infrastructure
Minaris Advanced Therapies has assembled a team of over 1,400 professionals who bring invaluable scientific and regulatory expertise to the table. This diverse team plays a crucial role in ensuring the highest standards of quality control, regulatory compliance, and analytical method development.
Commitment to Patient Care
Eytan Abraham, Ph.D., the chief commercial and technology officer, elaborates on the company’s vision: to enhance patient outcomes through innovative manufacturing practices. With technologies that aim to reduce costs and improve turnaround times, Minaris is focused on revolutionizing the treatment landscape.
Facilities and Resources
The company’s operational prowess is reflected in its expansive infrastructure, which includes 42 state-of-the-art clean rooms across several facilities. These locations not only ensure compliance with rigorous global health standards but also streamline the manufacturing process for commercial use.
Minaris Advanced Therapies has a legacy that speaks volumes, having undergone over 20 successful inspections by various global health agencies, including the FDA and EMA. The expertise in biosafety and product characterization is complemented by an impressive set of intellectual properties, including key advancements in scalable AAV and lentiviral vector production.
About Minaris Advanced Therapies
As a global contract development and manufacturing organization (CDMO) focused on cell and gene therapies, Minaris Advanced Therapies stands as a beacon of innovation within the industry. The company aims to expedite the transition from scientific discovery to patient delivery. Leveraging best-in-class manufacturing and testing services, Minaris is dedicated to ensuring that effective therapies reach patients more rapidly. With an impressive manufacturing history, Minaris continues to expand its impact on the healthcare landscape.
Frequently Asked Questions
What is Minaris Advanced Therapies?
Minaris Advanced Therapies is a global leader in the development, manufacturing, and testing of cell and gene therapies.
Where is Minaris headquartered?
The company is headquartered in Philadelphia and operates facilities across the United States, Europe, and Asia.
What kind of products does Minaris manufacture?
Minaris manufactures both clinical-stage and commercial cell therapy products, currently involved with two commercial cell therapies.
How does Minaris ensure quality in its services?
The company has over 1,400 professionals focusing on quality control, manufacturing, and compliance with global regulatory standards.
What is the mission of Minaris Advanced Therapies?
The mission is to help the industry treat more patients by innovating scalable manufacturing processes and facilitating the commercialization of promising therapies.
